LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Home・Aandelen Lijst・Avita Therapeutics Inc

Avita Therapeutics Inc

Gesloten

3.72 9.73

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.31

Max

3.76

Belangrijke statistieken
By Trading Economics
Inkomsten	3.9M -9.9M
Verkoop	-96K 18M
Winstmarge	-53.86
Werknemers	260
EBITDA	4M -8.1M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+120.59% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-39M 102M
Vorige openingsprijs	-6.01
Vorige sluitingsprijs	3.72

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

8.83 / 9.77 Steun & Weerstand

Avita Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 nov 2025, 23:38 UTC

Winsten

OCBC Posts Steady Third-Quarter Net Profit, Drop in Net Interest Income

6 nov 2025, 23:00 UTC

Winsten

Macquarie's First-Half Profit Grows 2.7%, Missing Forecasts -- Update

6 nov 2025, 22:19 UTC

Winsten

Belangrijke Marktbewegers

Block Shares Slide After 3Q Results Miss Estimates

6 nov 2025, 21:53 UTC

Winsten

Macquarie's First-Half Profit Grows 2.7%, Missing Forecasts

6 nov 2025, 23:45 UTC

Winsten

Wheaton Precious Metals 3Q Sales $476M >WPM

6 nov 2025, 23:45 UTC

Winsten

Wheaton Precious Metals 3Q Adj EPS 61.8c >WPM

6 nov 2025, 23:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

6 nov 2025, 23:45 UTC

Marktinformatie

Nikkei May Fall After U.S. Tech Stocks Drop -- Market Talk

6 nov 2025, 23:45 UTC

Winsten

Wheaton Precious Metals 3Q EPS 80.7c >WPM

6 nov 2025, 23:38 UTC

Marktinformatie

Gold Edges Higher Amid Worrisome Signs for U.S. Economy -- Market Talk

6 nov 2025, 23:15 UTC

Winsten

Kakao 3Q Net Profit Beat FactSet-Compiled Consensus

6 nov 2025, 23:14 UTC

Winsten

Kakao 3Q Net KRW192.86B Vs. Net KRW78.51B >035720.SE

6 nov 2025, 23:14 UTC

Winsten

Kakao 3Q Oper Pft KRW208.05B Vs. Pft KRW130.53B >035720.SE

6 nov 2025, 23:13 UTC

Winsten

Kakao 3Q Rev KRW2.087T Vs. KRW1.921T >035720.SE

6 nov 2025, 23:08 UTC

Winsten

Oversea-Chinese Banking Corp. 3Q Total Income S$3.80B Vs. S$3.80B >O39.SG

6 nov 2025, 23:08 UTC

Winsten

Oversea-Chinese Banking Corp. 3Q Noninterest Income S$1.57B Vs. S$1.37B >O39.SG

6 nov 2025, 23:07 UTC

Winsten

Oversea-Chinese Banking Corp. 3Q Net S$1.98B Vs. Net S$1.97B >O39.SG

6 nov 2025, 23:07 UTC

Winsten

Suzano 3Q Rev BRL12.2B >SUZ

6 nov 2025, 22:47 UTC

Acquisities, Fusies, Overnames

Wheaton Precious Metals to Pay Waterton Gold $670M Up Front

6 nov 2025, 22:47 UTC

Acquisities, Fusies, Overnames

Wheaton Precious Metals to Buy Gold Stream on Spring Valley Project Located in Nevada >WPM

6 nov 2025, 22:45 UTC

Acquisities, Fusies, Overnames

Union Pacific and Norfolk Southern Provide Supplemental Disclosures to Joint Proxy Statement About Merger

6 nov 2025, 22:25 UTC

Acquisities, Fusies, Overnames

At Bank of America's Investor Day, M&A Hints, Would-Be CEOs, and AI Pitches -- Barrons.com

6 nov 2025, 22:13 UTC

Winsten

Fairfax Financial 3Q Rev $8.27B >FFH.T

6 nov 2025, 22:02 UTC

Winsten

Century Aluminum 3Q Sales $632.2M >CENX

6 nov 2025, 22:02 UTC

Winsten

Century Aluminum 3Q Adj EPS 56c >CENX

6 nov 2025, 21:53 UTC

Winsten

DraftKings Stock Sinks on Disappointing Results -- Barrons.com

6 nov 2025, 21:52 UTC

Acquisities, Fusies, Overnames

Universal Display: Portfolio Includes More Than 300 Issued and Pending Patents Worldwide, Covering More Than 110 Unique Patent Families >OLED

6 nov 2025, 21:51 UTC

Acquisities, Fusies, Overnames

Universal Display Corp to Acquire Emissive OLED Patent Assets From Merck KGaA, Darmstadt, Germany

6 nov 2025, 21:50 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

6 nov 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Avita Therapeutics Inc Prognose

Koersdoel

By TipRanks

120.59% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 7.5 USD 120.59%

Hoogste 14 USD

Laagste 3 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Avita Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Avita Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

8.83 / 9.77Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.